Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Unstable angina: new insights into pathophysiologic characteristics, prognosis, and management strategies.

Current problems in cardiology·1996
Same author

Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.

The Journal of infection·1996
Same author

Preconditioning with ischemia or adenosine protects skeletal muscle from ischemic tissue reperfusion injury.

The Journal of surgical research·1996
Same author

A WHO Collaborative Study of Maternal Anthropometry and Pregnancy Outcomes.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·1996
Same author

Radiopacity of potential root-end filling materials.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics·1996
Same author

Changes in mast cell reactivity in the course of allergic inflammation.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·1996

相关实验视频

Updated: Jul 9, 2026

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
08:12

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS

Published on: November 26, 2018

乙烯酸和furosemide在患有慢性毛囊后肺高血压的患者中的急性血液动力学影响.

S M Austin, B F Schreiner, D H Kramer

    Circulation
    |February 1, 1976
    PubMed
    概括

    利尿剂,如乙烯酸和富洛塞米德,可以降低肺动脉压力,但在患有肺高血压的患者中不会显著改变肺血液体积或血管外液体. 这表明肺部运行在一个的压力-体积曲线上,延迟了液体分辨率.

    科学领域:

    • 心脏病学 心脏病学
    • 肺高血压是什么意思 肺高血压
    • 药理学 药理学是指药理学的学科.

    背景情况:

    • 肺高血压,特别是毛囊后高血压,通常与关节狭窄有关.
    • 利尿剂通常用于控制心血管疾病中的液体过载.

    研究的目的:

    • 为了研究乙烯酸和富洛塞米德在接受心脏导管治疗的患者的急性血液动力学效应.
    • 在注射尿剂后,评估肺血量 (PBV) 和肺外血管液量 (PEV) 的变化.

    主要方法:

    • 在27名患者中进行了右心脏和横心脏左心脏导管.
    • 测量心脏指数,压力,肺血液体积 (PBV) 和肺外血管液体体积 (PEV) 在注射利尿剂之前和之后.
    • 患者包括那些患有心肌狭窄引起的肺高血压和其他正常的肺动脉压力.

    主要成果:

    • 乙烯酸和富洛塞米德都导致肺动脉和左心房压力,心脏指数和血体积显著降低.
    • 尽管有这些减少,肺血液体积 (PBV),血管外体积 (EV) 和PEV与PBV的比率保持不变.
    • 系统性动脉压没有显著变化.

    结论:

    • 这项研究表明,在患有毛囊后肺高血压的患者中,肺血管可能在压力-体积曲线的的部分运行,导致尽管肺动脉压力降低,但PBV保持不变.

    更多相关视频

    Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
    07:59

    Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

    Published on: July 28, 2018

    Evaluation of Fluid Overload by Bioelectrical Impedance Vectorial Analysis
    07:17

    Evaluation of Fluid Overload by Bioelectrical Impedance Vectorial Analysis

    Published on: August 17, 2022

    相关实验视频

    Last Updated: Jul 9, 2026

    Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
    08:12

    Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS

    Published on: November 26, 2018

    Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
    07:59

    Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

    Published on: July 28, 2018

    Evaluation of Fluid Overload by Bioelectrical Impedance Vectorial Analysis
    07:17

    Evaluation of Fluid Overload by Bioelectrical Impedance Vectorial Analysis

    Published on: August 17, 2022

  • 这些发现支持了肺外血管空间抵抗肺毛细血管压力急性下降的概念,解释了缓解肺堵塞的延迟.
  • 利尿剂有效地降低了中心压力和液体体积,但在这个患者群体中不会急剧改变肺血液分布或血管外液体.